Over 8 million people. That is the number of people who might be alive today if the international community had accomplished the 100 Days Mission to develop safe and effective new vaccines against SARS-CoV-2 in three months. 👉 https://t.co/CZlwcJZEsW @imperialcollege

📣 The Republic of Korea's Ministry of Foreign Affairs @mofa_kr has announced new $18.9 million support to CEPI to bolster efforts to protect against the next deadly pandemic and boost international health security 🇰🇷 https://t.co/JfnlZwzqfW

📣 New for the agentic cloud: Azure Copilot—an immersive, full-screen command center powered by GPT-5 reasoning and a collection of agents to help you migrate, operate, and optimize your entire IT estate.

Science moves one step closer to a #Lassa fever vaccine. The first volunteer has now received a dose of the first-in-human Lassa vaccine in a cutting-edge Oxford trial, funded by @CEPIvaccines, marking a major step in safety & immune response testing. Read:

With today's announcement, both active CEPI-funded Lassa vaccines are now in clinical testing. (4/4)

Discussing the launch of the new trial, Katrin Ramsauer, Lassa Disease Programme Lead at CEPI, said: “While there is still important work ahead, this moment brings us closer to a future where communities no longer live in fear of this devastating disease.” (3/4)

🌍The deadly haemmorhagic fever causes regular outbreaks across West Africa, with hundreds of thousands of people estimated to be infected every year. However, despite its epidemic potential, no vaccine is currently available for use (2/4)

📣The first volunteer has received a dose of @UniofOxford's Lassa fever vaccine candidate in a Phase I trial funded by CEPI | @OxfordVacGroup 🧵 https://t.co/Fv6DlYy8M1

It was a great chance to connect with our partners and highlight the importance of science, innovation, and international partnership in strengthening pandemic preparedness and ensuring that lifesaving vaccines reach everyone who needs them.

At Aurum, the Vice Minister met researchers who had led CEPI-supported studies on COVID-19 vaccination in people living with HIV.

The visit showcased the Netherlands’ longstanding support for CEPI—which has been part of our Coalition since 2020—and highlighted the impact of CEPI-funded research in South Africa.

Last month, CEPI had the pleasure of welcoming Marjolijn Sonnema, Vice Minister of Health of the Netherlands, to The @Auruminstitute in Johannesburg.

CEPI’s November newsletter is out! 🗞️ This edition spotlights recent regulatory “pressure test” simulations in Brasilia and Mombasa, early clinical progress on a Lassa fever vaccine, new partnerships to speed up vaccine manufacturing and release, & more. https://t.co/Xo9c37InpO

CEPI’s new publication lays out the blueprint for equitable access at the heart of the organisation’s outbreak R&D. It details four pathogen archetypes which guide CEPI’s access funding, advocacy, and catalysing efforts. Learn more in the blog ⬇️ https://t.co/BF8kDmM2Iw

Strengthening lassa fever response starts with shared knowledge & coordinated action. @OoasWaho’s public launch webinar will convene leaders to drive stronger, evidence-based solution to lassa fever. The countdown is on. 4 days to go! Register: https://t.co/YoYzadnXEk

Prof. Jane Halton, Chair, CEPI, emphasises that health preparedness “is not a development problem or a welfare issue, but an issue of security, mutual self-protection, and global cooperation.” @CEPIvaccines @icmr_nie #OneHealth #NOHAssembly2025

Join @OoasWaho, CEPI & partners for a webinar launching the Lassa Fever Research Agenda & open-access Repository—key tools to guide research, inform policy, and support timely, equitable vaccine introduction. 📅 25 Nov | 🕛 12:00 GMT 🔗 Register: https://t.co/WIaGoFPwQf

By delivering rapid, high-resolution, and reproducible data, the approach not only accelerates vaccine release but also enhances quality assurance and safety across important development and manufacturing workflows, supprting CEPI's 100 Days Mission.

With up to $195,811 in CEPI support, LumaCyte is partnering with IDT Biologika to deploy its Radiance® instrument and advance a reagent-free potency assay using Laser Force Cytology™ (LFC). This novel label-free technology detects subtle cellular changes from viral infection or

These assays are vital for confirming a vaccine’s ability to trigger an immune response and often rely on time-consuming cell culture and reagent-based methods that can delay development and release by days or even weeks.

A new CEPI-funded initiative with @LumaCyte and @idtbiologika aims to overcome a major hurdle in vaccine manufacturing: the slow, complex process of potency testing.

Dr. @msdhingramd, Director R&D, @CEPIvaccines US Office and team, called on the @PrinSciAdvGoI, Prof. @AjaySoodIISc and Scientific Secretary Dr. Parvinder Maini to discuss developments in vaccine platforms and R&D capacities against priority diseases for India and other